Dallas, TX
Stem Cell Therapy clinics in Dallas
Dallas supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through UT Southwestern, Baylor, and Texas Health Presbyterian, and stem cell practice in the area spans Uptown, Preston Hollow, and Park Cities. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. House Bill 810 (2017) permits licensed Texas physicians to administer investigational adult stem cell treatments for patients with severe chronic diseases or terminal illnesses under institutional review board oversight, without an FDA Investigational New Drug authorization. Texas Medical Board licensure is required, and advertising is regulated under the Texas Occupations Code. The 23 Dallas clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Texas Medical Board licensure checks.
Innovations Stem Cell Center
- Shockwave Therapy
- Multiple Sclerosis (MS) Treatment
- Arthritis Treatment
- Lyme Disease Treatment
- Erectile Dysfunction (ED) Treatment
Wound Evolution - Wound Care and Hyperbaric Medicine
- Hyperbaric Oxygen Therapy (HBOT)
- Stem Cell Therapy
Texas Pain Physicians
- PRP Therapy
- Arthritis Treatment
- Migraine Treatment
- Stem Cell Therapy
MD on staff
Paradigm Wellness Medical Group
- PRP Therapy
- IV Therapy
- Arthritis Treatment
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
Dr. Leila Doolittle
- PRP Therapy
- Biofeedback Therapy
- Ozone Therapy
- Laser Therapy (LLLT)
- Arthritis Treatment
Hello Nurse Mobile IV Services
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Migraine Treatment
Regulatory context
A note on Texas's stem cell therapy rules.
Texas cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Texas for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Texas enacted a state-level investigational adult stem cell framework in 2017 that does not override federal law.
-
Texas HB 810 (2017), Texas Health and Safety Code Chapter 1003
Authorizes administration of investigational adult stem cell treatments to eligible patients with severe chronic or terminal illness when conducted by Texas-licensed physicians at facilities meeting defined institutional review board oversight criteria. -
Texas Medical Practice Act, Texas Occupations Code Title 3, Subtitle B
Establishes physician licensure and discipline through the Texas Medical Board. -
Texas Pharmacy Act, Texas Occupations Code Chapter 551 et seq
Regulates compounding pharmacies aligned with federal 503A and 503B standards.
The FDA has issued warning letters to Texas clinics offering stem cell and exosome therapies. The Texas Medical Board has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Texas Attorney General has used the Texas Deceptive Trade Practices Act to pursue providers making unsupported clinical claims. HB 810 expressly does not preempt federal law, so even Texas providers operating under HB 810 must comply with 21 CFR Part 1271 and remain subject to FDA enforcement if products fall outside Section 361.